



September 13, 2012

For Immediate Release

UMN Pharma Inc.

UNIGEN, a UMN Pharma Subsidiary, Designated as Gifu Prefectural Government's "Subsidy for Promotion of Establishment of New Business Facilities"

On 10 September, 2012, UNIGEN Inc. (Headquarters, Akita, Japan; CEO: Yasuo Amatsuji, Ph.D.) was designated as "Subsidy for Promotion of Establishment of New Business Facilities" administered by Gifu Prefectural Government. Following the selection in the first round of the public offering for the FY 2011 "Subsidy for Domestic Location Promotion Projects" administered by the Ministry of Economy, Trade and Industry (METI) on 3 February, 2012, this subsidy funds are planned to be used for an initial investment for fixed assets such as buildings and depreciable assets associated with the construction of Gifu plant. UNIGEN was designated for this subsidy because of its potential to attract new investments and because of job opportunities that are expected to be maintained and created from the new plant scheduled for construction in Gifu Prefecture.

The production facility to be constructed with the assistance of this subsidy program is a 5-floor steel frame structure with a total floor area of about 14,000m². This plant will use recombinant protein production technology based on insect cells and/or mammal cells to produce commercial drug substances in the rapidly-growing field of biopharmaceuticals. UNIGEN has already started operations of a pilot plant capable of process development in Akita Prefecture, and in addition to the flu vaccine that will be jointly developed by UMN Pharma Inc. and Astellas Pharma Inc., this plant will enable UNIGEN to handle the entire manufacturing process from initial development to large-scale commercial production in the manufacturing of biopharmaceutical drug substances.

For More Information, contact:
Business Development Division
Tel: +81-45-624-8341
e-mail: press@umnpharma.com